{
    "ticker": "CHEB",
    "name": "Chembio Diagnostics, Inc.",
    "description": "Chembio Diagnostics, Inc. is a leading developer of point-of-care diagnostic tests that focus on infectious diseases. Founded in 1985, Chembio is headquartered in Hauppauge, New York, and has established itself as a pioneer in the development of rapid diagnostic solutions that improve patient care and public health outcomes. The company's innovative product portfolio includes tests for diseases such as HIV, syphilis, and various viral infections. Chembio's proprietary DPP\u00ae technology (Dual Path Platform) allows for rapid and accurate testing, enabling healthcare providers to deliver timely diagnoses and treatments. Chembio\u2019s mission is to enable healthcare professionals to make informed decisions through accessible and reliable diagnostic testing, thereby enhancing patient outcomes. The company is committed to expanding its reach globally, partnering with organizations and governments to reduce the burden of infectious diseases. With a strong emphasis on research and development, Chembio is continuously working to innovate and bring new diagnostic tests to market that meet the evolving needs of healthcare providers and patients alike.",
    "industry": [
        "Medical Diagnostics",
        "Healthcare"
    ],
    "headquarters": "Hauppauge, New York, USA",
    "founded": "1985",
    "website": "https://www.chembio.com",
    "ceo": "Richard E. D. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/ChembioDx",
        "linkedin": "https://www.linkedin.com/company/chembio-diagnostics/"
    },
    "investor_relations": "https://investors.chembio.com",
    "key_executives": [
        {
            "name": "Richard E. D. McGowan",
            "position": "CEO"
        },
        {
            "name": "John A. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Infectious Disease Diagnostics",
            "products": [
                "DPP\u00ae HIV 1/2 Test",
                "DPP\u00ae Syphilis Screen Test"
            ]
        }
    ],
    "seo": {
        "meta_title": "Chembio Diagnostics, Inc. | Point-of-Care Diagnostic Solutions",
        "meta_description": "Explore Chembio Diagnostics, Inc., a leader in rapid diagnostic testing for infectious diseases. Discover innovative solutions that improve patient care.",
        "keywords": [
            "Chembio",
            "Diagnostics",
            "Infectious Diseases",
            "Point-of-Care Testing",
            "Rapid Tests"
        ]
    },
    "faq": [
        {
            "question": "What does Chembio Diagnostics specialize in?",
            "answer": "Chembio Diagnostics specializes in point-of-care diagnostic tests for infectious diseases."
        },
        {
            "question": "Where is Chembio headquartered?",
            "answer": "Chembio is headquartered in Hauppauge, New York, USA."
        },
        {
            "question": "What are some of Chembio's key products?",
            "answer": "Chembio's key products include the DPP\u00ae HIV 1/2 Test and the DPP\u00ae Syphilis Screen Test."
        },
        {
            "question": "When was Chembio founded?",
            "answer": "Chembio was founded in 1985."
        }
    ],
    "competitors": [
        "ABT",
        "BDX",
        "PFE",
        "RMD"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "JNJ",
        "AMGN"
    ]
}